logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences to fast track development of its coronavirus antibody & inhalation technology

Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO Dr Kunwar Shailubhai tells Proactive London's Andrew Scott they're accelerating a potential treatment for COVID-19 alongside a unique method of delivering the inhaled version of the drug.

As part of the fast-track process, he says the company has signed an agreement with STC Biologics for the good manufacturing practice (GMP) production of TZLS-501, a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.

Tiziana is also working with a firm called Sciarra Laboratories on a unique technology that sends the drug directly to the lungs using a handheld inhaler or nebuliser.

Quick facts: Tiziana Life Sciences PLC

Price: 82.5 GBX

AIM:TILS
Market: AIM
Market Cap: £160.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: FTSE calms as optimism vaccine news is challenged by rise in...

FTSE 100 had a lukewarm start on Wednesday as positive vaccine news can’t change the current rise in infections and global lockdowns. London’s leading index advanced 11 points to 6,308 in early dealing. JD Wetherspoon PLC (LON:JDW) has posted a 28% slump in sales over the past four months...

3 weeks, 2 days ago

2 min read